These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 34619153)

  • 1. Primary Determination of Particle Number Concentration with Light Obscuration and Dynamic Imaging Particle Counters.
    Ripple DC; DeRose PC
    J Res Natl Inst Stand Technol; 2018; 123():1-21. PubMed ID: 34877136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Clinical Safety and Analytical Impact of Subvisible Silicone Oil Particles in Biopharmaceutical Products.
    Saggu M; Bou-Assaf GM; Bucher R; Budyak IL; Buecheler J; Cao S; Groenning M; Khan E; Kwok SC; Minocha S; Pisupati K; Radhakrishnan V; Videbæk N; Yang DT; Zhang B; Narhi LO
    J Pharm Sci; 2024 May; 113(5):1401-1414. PubMed ID: 38220088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologically-Directed Raman Spectroscopy as an Analytical Method for Subvisible Particle Characterization in Therapeutic Protein Product Quality.
    Kim M; Ma Y; Srinivasan C; O'Connor T; Telikepalli SN; Ripple DC; Lute S; Bhirde A
    Sci Rep; 2023 Nov; 13(1):20473. PubMed ID: 37993487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number Concentration Measurements of Polystyrene Submicrometer Particles.
    DeRose PC; Benkstein KD; Elsheikh EB; Gaigalas AK; Lehman SE; Ripple DC; Tian L; Vreeland WN; Welch EJ; York AW; Zhang YZ; Wang L
    Nanomaterials (Basel); 2022 Sep; 12(18):. PubMed ID: 36144906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.
    Kiyoshi M; Shibata H; Harazono A; Torisu T; Maruno T; Akimaru M; Asano Y; Hirokawa M; Ikemoto K; Itakura Y; Iwura T; Kikitsu A; Kumagai T; Mori N; Murase H; Nishimura H; Oda A; Ogawa T; Ojima T; Okabe S; Saito S; Saitoh S; Suetomo H; Takegami K; Takeuchi M; Yasukawa H; Uchiyama S; Ishii-Watabe A
    J Pharm Sci; 2019 Feb; 108(2):832-841. PubMed ID: 30121316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interlaboratory comparison about feasibility of insoluble particulate matter test for injections with reduced test volume in light obscuration method.
    Harazono A; Shibata H; Kiyoshi M; Muto T; Fukuda J; Torisu T; Saitoh S; Nishimura H; Uchiyama S; Ishii-Watabe A
    Biologicals; 2019 Jan; 57():46-49. PubMed ID: 30553568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Laser Diffraction for Quantification of Protein Aggregates: Comparison With Resonant Mass Measurement, Nanoparticle Tracking Analysis, Flow Imaging, and Light Obscuration.
    Yoneda S; Niederleitner B; Wiggenhorn M; Koga H; Totoki S; Krayukhina E; Friess W; Uchiyama S
    J Pharm Sci; 2019 Jan; 108(1):755-762. PubMed ID: 30237029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of particulate matter in small volume antibiotic injections].
    Niizeki M; Tanno K
    Jpn J Antibiot; 1989 Mar; 42(3):567-72. PubMed ID: 2746842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus M; Werner BP; Geerling G; Winter G
    Retina; 2018 Oct; 38(10):2088-2095. PubMed ID: 28841584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Evaluation of Insoluble Particulate Matters in Therapeutic Protein Injections Using Light Obscuration and Flow Imaging Methods.
    Shibata H; Harazono A; Kiyoshi M; Ishii-Watabe A
    J Pharm Sci; 2022 Mar; 111(3):648-654. PubMed ID: 34619153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.